Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending.
Ultragenyx and Mereo Biopharma are expecting to report results from two phase 3 trials for Osteogenesis Imperfecta (OI), commonly known as brittle bone disease, at the end of 2025. Earlier in July, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback